ALLEN OLIFF, MD
Osteopathic Medicine in Gwynedd Valley, PA

6207798, Mar 27, 2001

Feb 10, 1997

8/798447

Allen I. Oliff - Gwynedd Valley PA
Gwynneth M. Edwards - Collegeville PA
Deborah D. Jones - Bala Cynwyd PA

Merck & Co., Inc. - Rahway NJ

C07K14/21, 7, A61K38/45

530350

We have modified PE. sub. 40 toxin by removing at least two of its four cysteine amino acid residues and have formed hybrid molecules containing modified PE. sub. 40 linked to a cell recognition protein that can be an antibody, a growth factor, a hormone, a lymphokine, or another polypeptide cell recognition protein for which a specific cellular receptor exists whereby the modified PE. sub. 40 toxin is directed to cell types having receptors for the cell recognition protein linked to the modified PE. sub. 40.

5019647, May 28, 1991

May 24, 1988

7/197872

Mark W. Riemen - Doylestown PA
Allen I. Oliff - Gwynedd Valley PA
Walfred S. Saari - Lansdale PA
David C. Heimbrook - Ringoes NJ

Merck & Co., Inc. - Rahway NJ

C07K 706, C07K 730, A61K 3743

530329

Small cell lung carcinoma cells (SCLC) contain gastrin releasing peptide (GRP) receptors. The response of the cells to GRP is rapid growth. We have found a group of peptide derivatives that act as GRP antagonists by blocking the binding of GRP to its receptor thereby inhibiting the growth of cells that are sensitive to the growth promoting activity of GRP.

4943561, Jul 24, 1990

Nov 28, 1988

7/276985

David C. Heimbrook - Ringoes NJ
Mark W. Riemen - Doylestown PA
Allen Oliff - Gwynedd Valley PA
Walfred S. Saari - Lansdale PA

Merck & Co., Inc. - Rahway NJ

A61K 3702, C07K 706

514 17

Small cell lung carcinoma (SCLC) cells contain gastrin releasing peptide (GRP) receptors. The response of the cells to GRP is rapid growth. We have found a group of peptide derivatives that act as GRP antagonists by blocking the binding of GRP to its receptor thereby inhibiting the growth of cells that are sensitive to the growth promoting activity of GRP.

5028692, Jul 2, 1991

Apr 25, 1989

7/343092

Allen I. Oliff - Gwynedd Valley PA
Walfred S. Saari - Lansdale PA

Merck & Co., Inc. - Rahway NJ

C07K 730, C07K 706, C07K 702, A61K 3743

530329

Small cell lung carcinoma cells (SCLC) contain gastrin releasing peptide (GRP) receptors. The response of the cells to GRP is rapid growth. We have found a group of peptide derivatives that act as GRP antagonists by blocking the binding of GRP to its receptor thereby inhibiting the growth of cells that are sensitive to the growth promoting activity of GRP.

4923878, May 8, 1990

Nov 14, 1988

7/270323

Joel R. Huff - Lederach PA
Allen I. Oliff - Gwynedd Valley PA

Merck & Co., Inc. - Rahway NJ

A61K 3144

514285

Compounds of formula I and its pharmaceutically acceptable salts are formulated with a pharmaceutical carrier for the treatment or prevention of neoplastic diesase states sensitive to such treatment in animals including humans ##STR1## wherein: A is an alkyl group having 1-6 carbons; X is oxygen, sulfur, or --NH--; R is hydrogen or an alkyl group having 1-6 carbons; and R. sub. 1 and R. sub. 2 are independently selected from the group consisting of hydrogen, a halogen a C. sub. 1-6 alkyl group, or C. sub. 1-3 alkoxy.

6989383, Jan 24, 2006

Jun 4, 1998

09/445054

Neal Rosen - Englewood NJ, US
Laura Sepp-Lorenzino - New Haven CT, US
Mark M. Moasser - New York NY, US
Allen I. Oliff - Gwynedd Valley PA, US
Jackson B. Gibbs - Chalfont PA, US
Nancy Kohl - Wyndmoor PA, US
Samuel L. Graham - Schwenksville PA, US
George C. Prendergast - Bala Cynwyd PA, US

Sloan-Kettering Institute For Cancer Research - New York NY

A61K 31/495, A61K 31/50, A61K 31/335, A61K 31/35, A61K 31/34

51425405, 51425501, 51425502, 514449, 514459, 514471, 514616

The present invention relates to methods of treating cancer using a combination of a compound which is an antineoplastic agent and a compound which is a inhibitor of prenyl-protein transferase, which methods comprise administering to said mammal, either sequentially in any order or simultaneously, amounts of at lest two therapeutic agents selected from a group consisting of a compound which is an antineoplastic agent and a compound which is an inhibitor or prenyl-protein transferase. The invention also relates to methods of preparing such compositions.

6177404, Jan 23, 2001

Aug 3, 1998

9/051759

Deborah DeFeo-Jones - Lansdale PA
Raymond E. Jones - Lansdale PA
Allen I. Oliff - Gwynedd Valley PA
Edward M. Scolnick - Wynnewood PA
Victor M. Garsky - Blue Bell PA

Merck & Co., Inc. - Rahway NJ

A61K 3816

514 8

Novel pharmaceutical compositions useful for the treatment of benign prostatic hyperplasia which comprises novel oligopeptides, which are selectively cleaved by enzymatically active PSA, in conjugation with a cytotoxic agent are described. Methods of treating benign prostate hypertrophy are also disclosed.

5690928, Nov 25, 1997

Apr 11, 1994

8/224422

David C. Heimbrook - Ringoes NJ
Allen I. Oliff - Gwynedd Valley PA
Steven M. Stirdivant - Warrington PA
Janet Ahern - Horsham PA

Merck & Co., Inc. - Rahway NJ

A61K 3845

424 945

Methods and compositions for treating bladder cancer using TGF-alpha or EGF fused to PE. sub. 40 or cysteine modified derivatives are taught. Also, a method of producing TGF-alpha-PE. sub. 40 derivatives of enhanced potency is described.

6143864, Nov 7, 2000

Jun 6, 1995

8/468161

Deborah DeFeo-Jones - Lansdale PA
Dong-Mei Feng - Harleysville PA
Victor M. Garsky - Blue Bell PA
Raymond E. Jones - Lansdale PA
Allen I. Oliff - Gwynedd Valley PA

Merck & Co., Inc. - Rahway NJ

A61K 3814, C07K 900

530322

Oligopeptides which comprise amino acid sequences that are recognized and proteolytically cleaved by free prostate specific antigen (PSA) are described. Also described are assays which comprise such oligopeptides useful for determining free PSA protease activity in vitro and in vivo. Therapeutic agents which comprise conjugates of such oligopeptides and known cytotoxic agents are also described.

5866679, Feb 2, 1999

Oct 6, 1995

8/540412

Deborah DeFeo-Jones - Lansdale PA
Victor M. Garsky - Blue Bell PA
Dong-Mei Feng - Harleysville PA
Raymond E. Jones - Lansdale PA
Allen I. Oliff - Gwynedd Valley PA

Merck & Co., Inc. - Rahway NJ

C07K 509, A61K 3800

530322

Oligopeptides which comprise amino acid sequences that are recognized and proteolytically cleaved by free prostate specific antigen (PSA) are described. Also described are assays which comprise such oligopeptides useful for determining free PSA protease activity in vitro and in vivo. Therapeutic agents which comprise conjugates of such oligopeptides and known cytotoxic agents are also described.